Aristotle Capital Boston LLC Has $14.91 Million Stake in Novanta Inc. $NOVT

Aristotle Capital Boston LLC raised its stake in shares of Novanta Inc. (NASDAQ:NOVT) by 21.4% in the 3rd quarter, Holdings Channel reports. The firm owned 148,885 shares of the technology company’s stock after purchasing an additional 26,229 shares during the quarter. Aristotle Capital Boston LLC’s holdings in Novanta were worth $14,911,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Novanta by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 4,378,888 shares of the technology company’s stock valued at $438,546,000 after buying an additional 193,366 shares during the last quarter. Wasatch Advisors LP raised its position in shares of Novanta by 10.6% during the second quarter. Wasatch Advisors LP now owns 1,100,029 shares of the technology company’s stock worth $141,827,000 after acquiring an additional 104,985 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Novanta by 1.4% during the second quarter. Geode Capital Management LLC now owns 919,666 shares of the technology company’s stock worth $118,585,000 after acquiring an additional 12,789 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Novanta by 4.2% in the third quarter. JPMorgan Chase & Co. now owns 753,111 shares of the technology company’s stock worth $75,424,000 after acquiring an additional 30,674 shares during the period. Finally, Champlain Investment Partners LLC lifted its stake in shares of Novanta by 16.5% in the second quarter. Champlain Investment Partners LLC now owns 694,691 shares of the technology company’s stock worth $89,567,000 after acquiring an additional 98,501 shares during the period. 98.35% of the stock is owned by institutional investors and hedge funds.

Novanta Stock Down 2.3%

Shares of NASDAQ:NOVT opened at $116.76 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.80 and a current ratio of 3.69. Novanta Inc. has a 52-week low of $98.27 and a 52-week high of $149.95. The business’s 50 day simple moving average is $135.29 and its two-hundred day simple moving average is $121.16. The firm has a market cap of $4.17 billion, a P/E ratio of 79.97 and a beta of 1.61.

Novanta (NASDAQ:NOVT) last released its quarterly earnings data on Monday, February 23rd. The technology company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novanta had a return on equity of 13.12% and a net margin of 5.49%.The firm had revenue of $258.35 million during the quarter, compared to the consensus estimate of $260.72 million. During the same quarter in the previous year, the company posted $0.76 earnings per share. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q1 2026 guidance at 0.750-0.800 EPS. As a group, research analysts forecast that Novanta Inc. will post 3.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Novanta news, CFO Robert Buckley sold 1,423 shares of the firm’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $140.88, for a total value of $200,472.24. Following the transaction, the chief financial officer directly owned 93,814 shares of the company’s stock, valued at approximately $13,216,516.32. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthijs Glastra sold 7,500 shares of Novanta stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $145.04, for a total transaction of $1,087,800.00. Following the transaction, the chief executive officer owned 57,367 shares of the company’s stock, valued at $8,320,509.68. This represents a 11.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 24,346 shares of company stock valued at $3,382,737 in the last 90 days. 1.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NOVT. Zacks Research raised shares of Novanta from a “strong sell” rating to a “hold” rating in a research report on Friday, January 16th. Robert W. Baird set a $150.00 price target on shares of Novanta in a research report on Wednesday, February 25th. Finally, Weiss Ratings raised shares of Novanta from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 20th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat, Novanta has a consensus rating of “Hold” and an average price target of $150.00.

Novanta Profile

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.